|
市場調查報告書
脊髓損傷：具有數10億美金潛在性魅力的利基市場
Stakeholder Opinions: Spinal Cord Injury - Attractive niche market with multi-billion dollar potential
| 出版商 |
Datamonitor |
| 出版日期 |
2010年03月 |
商品編碼 |
115574 |
| 內容資訊 |
英文 Pages: 124 |
| 價格 |
|
|
脊髓損傷：具有數10億美金潛在性魅力的利基市場 是由出版商Datamonitor在2010年03月所出版的。
這份英文市場調查報告書包含Pages: 124 價格從美金3800起跳。
歐巴馬總統對人體ES細胞研究限制之下、今後是脊髓損傷領域新時代的來臨。
本報告書內容包括:全球7大市場的脊髓損傷病患動向、脊髓損傷的治療需求和目前的藥物生產線、治療藥開發業者所直接面臨的機會和威脅脅、內容綱要摘記如下:
概要
實施摘要
脊髓損傷：病患動向
- 調查結果
- 脊髓損傷的定義
- 脊髓損傷的病因學
- 脊髓損傷的病態生理學
- 脊髓損傷的診斷
- 脊髓損傷的免疫學
- 脊髓損傷的經濟性效果
目前的治療法和尚未被滿足的需求
- 調查結果
- 針對脊髄損傷目前的管理
- 病患照護路徑
- 脊髄損傷的尚未被滿足的需求
市場潛在性
藥物生產線分析
- 調查結果
- 脊髓損傷的治驗設計
- 臨床藥物生產線概要
- Cethrin
- XP19986
- ProCord
- ATI355
- 事故移植併用肝細胞療法
- Astrostem
- Neu2000
- Cordaneurin
- 前臨床藥物生產線概要
- 被禁止的藥物生產線候補藥
- 未來的治療法
參考資料
附錄
圖表
Abstract
Introduction
Advances in understanding the pathophysiology of spinal cord injury (SCI) over
the past 2 decades have given rise to several therapeutic strategies that are
presently being examined in Phase II/I clinical trials. Furthermore, President
Obama' s March 2009 decision to overturn restrictions on human embryonic stem
cell research represents a new era in the field of spinal cord injuries.
Scope of this research
- Analysis of the patient potential of spinal cord injury across the seven
major markets and rest of world.
- Review of key unmet clinical needs in the treatment of spinal cord injury
and current pipeline treatments.
- Identification of key opportunities and threats facing developers of
treatments for spinal cord injury.
- Insight from four internationally recognized key opinion leaders in the
field of spinal cord injuries.
Research and analysis highlights
Therapeutic interventions for SCI need not necessarily provide a complete
restoration of anatomic connections in order to lead to functional
improvements and enhance patients' quality of life. Controversy continues to
surround the use of methylprednisolone as an acute treatment for SCI,
indicating a need for approved neuroprotective treatments.
Alseres Pharmaceuticals' s Cethrin (a recombinant fusion protein) has
demonstrated a measurable effect on neurological recovery after SCI in a Phase
I/IIa clinical trial. However, with its Phase II clinical program currently on
hold, future development of Cethrin is uncertain.
President Obama' s March 2009 decision to lift restrictions on US federal
funding for research involving human embryonic stem cells has provided
developers with a greater deal of freedom with regards to research into SCI.
Key reasons to purchase this research
- Quantify the incidence of spinal cord injury and identify key clinical
unmet needs.
- Assess the opportunities and threats facing developers in the spinal cord
injury market.
- Utilize pipeline product profiles to identify potential in-licensing
opportunities.
Table of Contents
OVERVIEW
EXECUTIVE SUMMARY
- Strategic scoping and focus
- Datamonitor insight into the spinal cord injury market
- Upcoming reports
SPINAL CORD INJURY: PATIENT POTENTIAL
- Key findings
- Definition of spinal cord injury
- Classification of spinal cord injury
- Etiology of spinal cord injury
- Road traffic accidents are the leading cause of SCI in developed
countries
- Pathophysiology of spinal cord injury
- Primary injury
- Secondary injury
- Diagnosis of spinal cord injury
- Epidemiology of spinal cord injury
- Seven major markets
- Rest of the world
- Epidemiological trends in spinal cord injury
- Economic consequences of spinal cord injury
CURRENT TREATMENT PRACTICES AND UNMET NEEDS
- Key findings
- Current management of spinal cord injury
- Surgery
- Methylprednisolone is a pharmacological treatment option for acute
spinal cord injury
- Rehabilitation
- Patient care path
- The acute hospital setting is the key intervention point for
neuroprotective treatments
- For manufacturers of neurorestorative treatments, rehabilitation and
community settings are key targets
- Further opportunities exist in the management of complications of SCI
- Unmet need in spinal cord injury
- Neurorestorative treatments
- Neuroprotective treatments
- Symptomatic treatments
MARKET POTENTIAL
- Key findings
- Datamonitor' s estimate of market potential
- Spinal cord injury: opportunities and threats
PIPELINE ANALYSIS
- Key findings
- Clinical trial design in spinal cord injury
- ICCP guidelines for the conduct of clinical trials in spinal cord injury
- Clinical pipeline overview
- Novartis represents the only Big Pharma company in the sparse clinical
pipeline for SCI
- The pipeline is dominated by neurorestorative treatments for acute SCI
- Cethrin (BA-210; Alseres Pharmaceuticals)
- Drug profile: intraoperatively administered Rho GTPase protein inhibitor
- Development overview
- Product positioning
- SWOT analysis
- XP19986 (arbaclofen placarbil; Xenoport)
- Drug profile: GABAb receptor agonist in Phase II development for
spasticity due to SCI
- Development overview
- Product positioning
- SWOT analysis
- ProCord (Proneuron Biotechnologies)
- Drug profile: autologous blood-derived macrophage therapy for the
treatment of acute SCI
- Development overview
- Product positioning
- ATI355 (reticulon 4 monoclonal antibody; Novartis AG)
- Drug profile: first human monoclonal antibody to neutralize Nogo-A
- Development overview
- Product positioning
- Autologous Combination Stem Cell Therapy (TCA Cellular Therapy)
- SCI represents the least advanced indication for Autologous Combination
Stem Cell Therapy
- Astrostem (RNL Bio)
- Human clinical study of Astrostem approved by Korean FDA in April 2009
- Neu2000 (Neurotech Pharmaceuticals)
- Improved locomotor outcomes associated with Neu2000 in rat model of
moderate SCI
- Cordaneurin (Spinal Cord Therapeutics)
- Cordaneurin prevents the formation of growth inhibiting scars
- Preclinical pipeline overview
- Spinal Cord Therapeutics and SanBio represent key developers in the
preclinical SCI pipeline
- Initiation of world' s first human clinical trial of embryonic stem
cell-based therapy is expected in Q3 2010
- Neureva is presently seeking a co-development partner for NVA0011
(gacyclidine)
- Discontinued pipeline candidates for spinal cord injury
- The future of treatment in spinal cord injury
- Key opinion leaders view partially restorative therapies to be the most
likely advance in the mid-term
- Combination treatments offer the greatest potential according to key
opinion leaders
- Geographical availability of efficacious SCI treatments will be limited
by expertise of physicians and cost
BIBLIOGRAPHY
- Books and journal papers
- Websites
- Datamonitor reports
APPENDIX
- Contributing experts
- Conferences attended
- Report methodology
TABLES
- Table: ASIA impairment scale
- Table: Studies of the incidence of spinal cord injuries in the seven major
markets
- Table: Incidence of spinal cord injury in the seven major markets, 2010 -
2020 (actual numbers)
- Table: Studies of the incidence of spinal cord injuries in the rest of the
world
- Table: Incidence of spinal cord injury in the rest of world markets, 2010
- 2020 (actual numbers)
- Table: Average yearly healthcare and living expenses and estimated
lifetime costs directly attributable to spinal cord injury
- Table: Studies of the prevalence of neuropathic pain in the spinal cord
injury population
- Table: Results of published studies investigating the efficacy of oral
pharmacological treatments in neuropathic spinal cord injury pain
- Table: Estimation of the US spinal cord injury market potential
- Table: Spinal cord injury market opportunities and threats
- Table: Products in clinical development for spinal cord injury, 2010
- Table: Cethrin - drug profile, 2010
- Table: Key facts: Phase II trial of Cethrin in patients with acute spinal
cord injury
- Table: XP19986 - drug profile, 2010
- Table: ProCord - drug profile, 2010
- Table: Key facts: Phase II trial of ProCord in patients with complete
spinal cord injury
- Table: ATI355 - drug profile, 2010
- Table: Key facts: Phase I trial of ATI355 in patients with acute spinal
cord injury
- Table: Products in preclinical development for spinal cord injury, 2010
- Table: Discontinued R&D projects in spinal cord injury, 2002 - 2010
FIGURES
- Figure: Key causes of traumatic spinal cord injury in the US, 2005 - 09
- Figure: Spinal cord injury patient care path
- Figure: Key unmet clinical needs in spinal cord injury, 2010
- Figure: Comparison of incentives conferred by orphan product policies
across the US, EU and Japan, 2010
- Figure: Guidelines for the conduct of clinical trials for spinal cord
injury as developed by the ICCP panel
- Figure: Composition of clinical pipeline for spinal cord injury by stage
of development
- Figure: Cethrin: Phase I/IIa trial results
- Figure: Cethrin: SWOT analysis
- Figure: XP19986: Phase II trial results
- Figure: XP19986: SWOT analysis
- Figure: Autologous activated macrophage therapy: Phase I trial results
|
